Welcome to our dedicated page for Harrow Health news (Ticker: HROW), a resource for investors and traders seeking the latest updates and insights on Harrow Health stock.
Harrow, Inc. (Nasdaq: HROW) is an ophthalmic-focused pharmaceutical company that regularly issues news and updates related to its portfolio of eye-care products, development programs, and corporate activities. The company describes itself as a leading provider of ophthalmic disease management solutions in North America, with products that address conditions such as dry eye disease, wet age-related macular degeneration, cataracts, refractive errors, glaucoma, ocular surface conditions, and retina diseases.
News about Harrow commonly covers financial results and investor communications, including quarterly earnings releases, letters to stockholders, and conference call announcements. The company also announces participation in investor conferences and Investor & Analyst Day events, where it provides overviews of its commercial portfolio, pipeline, and long-term vision.
Another key theme in Harrow’s news flow is business development and pipeline progress. Recent press releases have described the agreement to acquire, and subsequent closing of the acquisition of, Melt Pharmaceuticals, Inc., a clinical-stage company developing non-opioid, non-IV sedation therapies such as MELT-300 and MELT-210. Harrow has used these announcements to explain the strategic rationale for expanding into procedural sedation and to outline regulatory and development milestones for these product candidates.
Harrow’s news also highlights access and affordability initiatives, such as the launch of the VEVYE Access for All (VAFA) program for VEVYE (cyclosporine ophthalmic solution) 0.1% and the broader Harrow Access for All (HAFA) program, which is intended to extend a unified access model across its branded, authorized generics, and compounded ophthalmic medications. Additional releases address leadership changes at ImprimisRx, debt offerings and related credit facilities, and other corporate matters.
Investors and eyecare professionals reviewing Harrow’s news page can expect updates on earnings, capital markets transactions, acquisitions, development milestones for ophthalmic and procedural sedation candidates, and initiatives aimed at improving patient access to the company’s ophthalmic therapies.
Harrow Health (NASDAQ: HROW) has entered an agreement with Sintetica, S.A. to acquire marketing and supply rights for AMP-100, an innovative ophthalmic surgical drug candidate for ocular surface anesthesia. This acquisition targets a market with over 10 million procedures annually in the U.S. AMP-100's safety and efficacy are backed by a comprehensive clinical program and a successful Phase 3 study. Sintetica plans to submit a New Drug Application to the FDA in late 2021. Harrow aims to leverage its commercial platform to maximize AMP-100's market potential.
Harrow Health, Inc. (NASDAQ: HROW) announced the release of its financial results for Q2 and six months ended June 30, 2021, scheduled for August 10, 2021, post-market. The company will share its second-quarter letter to stockholders on its website. A conference call and live webcast will follow at 4:45 PM ET to discuss results and provide a business update. Harrow Health is focused on ophthalmology, operating ImprimisRx and Visionology, and holds equity positions in Eton Pharmaceuticals, Surface Ophthalmics, and Melt Pharmaceuticals.
NovaBay Pharmaceuticals (NYSE American: NBY) has partnered with ImprimisRx, a subsidiary of Harrow Health (Nasdaq: HROW), for the promotion of its product Avenova, a 0.01% hypochlorous acid solution for eye care. This collaboration aims to enhance national sales, marketing, and distribution efforts for Avenova, which addresses chronic eye conditions affecting 30 million Americans. The partnership is expected to improve accessibility to prescription Avenova through a streamlined pharmaceutical model.
Harrow Health, Inc. (NASDAQ: HROW) announced two newly issued patents related to ophthalmic compositions for intraocular administration. These patents, dated May 4 and June 29, 2021, enhance Harrow's portfolio in surgical dilation agents, particularly for cataract surgeries. Data regarding a compounded mydriatic drug combination will be presented at the ASCRS 2021 Annual Meeting, demonstrating effective pupil dilation. This advancement positions Harrow Health for growth within the ophthalmic market, supporting over 250,000 cataract procedures annually.
Harrow Health (NASDAQ: HROW) announced the closure of its public offering, raising $20 million through the issuance of 8.625% senior notes due 2026. This includes a $2.5 million over-allotment option. The net proceeds of approximately $19.6 million will be used to redeem Series B Cumulative Preferred Stock and for general corporate purposes, including future product acquisitions. The notes, rated "BB" by Egan-Jones Ratings, will trade on Nasdaq under the symbol 'HROWL'.
Harrow Health (NASDAQ: HROW) has priced its underwritten public offering of $17.5 million in 8.625% senior notes due 2026. The offering, expected to close on June 17, 2021, may increase by $2.5 million if the underwriters exercise their option. The notes will be priced at $25.75 each, yielding aggregate proceeds of $18,025,000. Proceeds will be utilized to redeem Series B Cumulative Preferred Stock and support general corporate purposes. Both the new and existing notes are rated 'BB' by Egan-Jones Ratings Company and will trade on Nasdaq under the symbol 'HROWL'.
Harrow Health (NASDAQ: HROW) has initiated an underwritten registered public offering of $17.5 million in 8.625% senior notes due 2026. These notes will trade alongside the existing notes of the same series. The proceeds are intended to redeem all outstanding Series B Cumulative Preferred Stock and for general corporate purposes, including product acquisitions and capital expenditures. Harrow Health's notes received a 'BB' rating from Egan-Jones Ratings Company. The offering will be conducted under the effective shelf registration statement filed with the SEC.
Harrow Health (NASDAQ: HROW), an ophthalmic-focused healthcare company, has launched a redesigned corporate and investor website aimed at enhancing user experience and accessibility of historical and current information. The site showcases Harrow's journey as a leading eye health provider, featuring its mission, product pipeline, and commitment to accessible eyecare. Key assets include ImprimisRx and Visionology, along with equity stakes in several pharmaceutical companies. The site also includes Letters to Stockholders and a Corporate Presentation to facilitate investor engagement.
Harrow Health, Inc. (NASDAQ: HROW) announced a multi-center retrospective study demonstrating significant improvements in patients with dry eye disease using its Klarity-C Drops® (cyclosporine 0.1%). Published in Clinical Ophthalmology, the study involved 50 patients and showed a marked decrease in ocular surface disease index (OSDI) scores and corneal staining grades after three months of treatment. The study highlighted no adverse events and emphasized Klarity-C's advantages over existing treatments, including its affordability and lack of insurance hurdles.
Harrow Health reported record first-quarter 2021 results, achieving revenues of $15.4 million, up 31% from $11.8 million year-over-year. Adjusted EBITDA reached $4.3 million, significantly higher than the previous year's $0.4 million. Segment contribution from ImprimisRx rose to $5.7 million, while DEXYCU® sales commissions increased 39% over Q4 2020, totaling $485,000. GAAP operating income improved to $2.9 million from an operating loss of $0.6 million, and gross margins increased to 75.6%, compared to 69% last year.